سعر جرين الفا 3 مليون وحدة دولية / مل (1 مل) 2022

Green-Alpha interferon alfa injection 3 MIU/ml, 1 ml, by Green Cross (Korea), imported by EIMC; a prescription-type biologic used under specialist supervision.

• In the reference SmPC, about two thirds of cancer patients had anorexia and half had nausea; flu-like syndrome is frequent. Leucopenia, thrombocytopenia, anaemia, thyroid dysfunction, autoimmune disorders and cardiovascular effects (transient hypotension, hypertension, oedema, arrhythmia, palpitations, chest pain) are reported.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France

• History of hypersensitivity to recombinant interferon alfa-2a or any excipient.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Severe pre-existing cardiac disease or history of cardiac disease.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Severe renal, hepatic or bone-marrow dysfunction.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Uncontrolled epilepsy and/or compromised central nervous system function.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Advanced decompensated chronic hepatitis or liver cirrhosis; chronic hepatitis in patients recently or currently treated with immunosuppressive agents.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France

• Severe psychiatric reactions, including depression, suicidal ideation, suicide attempts and suicide, may occur with or without previous psychiatric history; monitor all patients for depression.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Serious bacterial, viral or fungal infections have been reported with alfa interferons; persistent fever should be investigated, particularly in neutropenic patients.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Should be given under the supervision of a qualified physician experienced in the indication; stop treatment if a hypersensitivity reaction occurs.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France

• TheophyllineInterferon alfa-2a has been reported to reduce theophylline clearance.ANSM (Agence nationale de securite du medicament), France
• Centrally acting drugs and drugs with neurological, haematological or cardiac toxicityInteractions with centrally acting drugs are possible, and the neurological, haematological or cardiac toxicity of previously or concomitantly given drugs may be increased by interferons.ANSM (Agence nationale de securite du medicament), France

• Insufficient data in pregnant women; an abortifacient effect was seen in rhesus monkeys at doses far above the clinical dose. Use in pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus; men and women receiving it should use effective contraception. Combination with ribavirin is teratogenic/embryotoxic.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France
• Excretion in breast milk is unknown; choose between stopping breastfeeding or stopping treatment based on the benefit of treatment to the mother.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France

• Monitor all patients for signs of depression; investigate persistent fever for serious infection.General active-ingredient information · ANSM (Agence nationale de securite du medicament), France

English text not available for this section.